Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus
Bruton Tyrosine Kinase (BTK) has a key role in multiple pathways involved in inflammation and autoimmunity. Therefore, BTK has become a new therapeutic target for a group of hematologic and autoimmune disorders. The pharmaceutical industry has invested in the clinical development of BTK inhibitors d...
Main Authors: | Aikaterini Patsatsi, Dedee F. Murrell |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.708071/full |
Similar Items
-
Rilzabrutinib-induced transition from <i>pemphigus vulgaris</i> to <i>pemphigus foliaceous</i>: case report and review of the literature
by: Christian Ciolfi, et al.
Published: (2024-10-01) -
Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
by: Piyu Parth Naik
Published: (2022-01-01) -
Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective
by: Yekta Ghane, et al.
Published: (2023-12-01) -
Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus
by: Christina Jiang, BS, MS, et al.
Published: (2023-12-01) -
An Updated Review of Pemphigus Diseases
by: Ali M. Malik, et al.
Published: (2021-10-01)